hsa glp-1 SDS-PAGE Analysis of GLP-1/HSA in the Process of IMS. Low range protein Designing GLP-1 delivery: structural perspectives

Martin Holst Lange, Executive Vice President and Chief Scientific Officer at Novo Nordisk, said, said the findings reinforced confidence in the combination while the wider trial programme continued

With these data in hand, Hengrui plans to take ribupatide into late-stage development in China

We look forward to working with you to provide quality service for our members

To establish remote ischaemic preconditioning, blood supply to the lower limbs was interrupted for 15 min by placing clamps on both femoral arteries at the proximal level 1 cm below the inguinal ligament 25 min before the onset of coronary ischaemia